ID   2B8 [Human Burkitt lymphoma]
AC   CVCL_6354
DR   CLO; CLO_0001246
DR   ATCC; CRL-12569
DR   cancercelllines; CVCL_6354
DR   Cell_Model_Passport; SIDM01262
DR   LINCS_LDP; LCL-2015
DR   Wikidata; Q54584309
RX   Patent=US6136599;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, American Type Culture Collection (ATCC); CRL-12569.
CC   Population: African; Nigerian.
CC   Selected for resistance to: ChEBI; CHEBI:9555; Tioguanine (6-thioguanine; 6-TG).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr163His (c.487T>C); ClinVar=VCV000376680; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Glu287Ter (c.859G>T); Zygosity=Unspecified (from parent cell line).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C27694; EBV-related Burkitt lymphoma
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_W740 ! HH514-16
SX   Male
AG   7Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 29
//
RX   Patent=US6136599;
RA   Cho M.-S.;
RT   "Human hybrid host cell for mammalian gene expression.";
RL   Patent number US6136599, 24-Oct-2000.
//